Response to the Letter to the Editor Entitled “Critical Reappraisal of Obinutuzumab Randomized Trials in Membranous Nephropathy”
Kajaree Giri, Richard J Glassock, Fernando C Fervenza · 2026
Read Response to the Letter to the Editor Entitled “Critical Reappraisal of Obinutuzumab Randomized Trials in Membranous Nephropathy” by Kajaree Giri, Richard J Glassock, Fernando C Fervenza (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13427534.txt.
Description
Giri, Glassock, and Fervenza reply to critics of obinutuzumab trials in primary membranous nephropathy, a kidney disease. They concede the MAJESTY trial ideally would have tested obinutuzumab against rituximab, the current standard. But a trial to prove it better would need 1,005 to 3,684 randomized patients. The range hinged on the remission rates assumed, making such a trial too big to run. Beating tacrolimus could still win United States approval. It could also help patients who cannot get rituximab paid for.
Catalog record
| CREATOR | Kajaree Giri, Richard J Glassock, Fernando C Fervenza |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 3 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |